To include your compound in the COVID-19 Resource Center, submit it here.

BMS-955176: Additional Phase IIa data

Data from 60 patients with HIV-1 subtype B in the open-label Part A portion of the international Phase IIa AI468002 trial showed that once-daily oral BMS-955176 reduced median HIV-1 RNA levels from baseline

Read the full 338 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers